Jake Simson - 28 May 2026 Form 4 Insider Report for Tyra Biosciences, Inc. (TYRA)

Reporting relationship: Director
Issuer ticker: TYRA
Reported as of: 28 May 2026
Net transaction value: $0
SEC form: 4
Accepted by SEC: 01 Jun 2026, 16:30:10 UTC
Prior SEC filing: 20 Jun 2025
Next SEC filing: 09 Jun 2026
Source filing: View source filing
Reporting owner signature: /s/ Ali D. Fawaz, Attorney-in-Fact

Key filing fact

Jake Simson filed Form 4 for Tyra Biosciences, Inc. (TYRA) on 01 Jun 2026.

Key facts

This page summarizes Jake Simson's Form 4 filing for Tyra Biosciences, Inc. (TYRA).
1 reported transaction and 1 derivative row are listed below.
Accepted by SEC: 01 Jun 2026, 16:30.

Change

Previous filing in this sequence was filed on 20 Jun 2025.
Current net transaction value: $0.

Research use

This tells you what this filing adds before you inspect full transaction and derivative tables.
You can trace every row back to the original SEC filing document.

Evidence

Filed on Form 4

Ownership activity is grounded in SEC Form 4 disclosures.

View source filing

Reporting Owners (1)

CIK 0001863094 Primary reporting owner

Simson Jake

Relationship: Director
Address: C/O TYRA BIOSCIENCES, INC., 2656 STATE STREET, CARLSBAD
Signature: /s/ Ali D. Fawaz, Attorney-in-Fact
Signature date: 01 Jun 2026

Reported derivative securities

Options, warrants, convertible securities, or similar derivative positions disclosed in the filing.

TYRA transaction Derivative

Stock Option (Right to Buy)

Award

Transaction value
Shares: +13,160
Change %
Price: $0.000000^*
Shares after: 13,160
Date: 28 May 2026
Ownership: Direct
Underlying class: Common Stock
Underlying amount: 13,160
Exercise price: $32.68
Footnotes: F1, F2

^* marks a reported price that did not pass the local price check.

Additional SEC filing notes

Filing notes and footnotes

Explanation of responses 2 footnotes

Footnote F1

The option was granted pursuant to the Issuer's Non-Employee Director Compensation Program. 1/12th of the total number of shares of common stock subject to the option vest monthly following May 28, 2026, the date of grant. In the event the next occurring annual meeting of the Issuer's stockholders occurs prior to the first anniversary of the date of grant, any remaining unvested portion of the option will vest on the date of such annual meeting of the Issuer's stockholders, subject to the Reporting Person's continuous service to the Issuer through each vesting date.

Footnote F2

Under the Reporting Person's arrangement with RA Capital Management, L.P. (the "Adviser"), the Reporting Person holds the stock option for the benefit of the RA Capital Healthcare Fund, L.P. (the "Fund"), the RA Capital Nexus Fund, L.P. (the "Nexus Fund"), and a separately managed account (the "Account"). The Reporting Person is obligated to turn over to the Adviser any net cash or stock received upon exercise of the stock option, which will offset advisory fees owed by the Fund, the Nexus Fund, and the Account to the Adviser. The Reporting Person therefore disclaims beneficial ownership of the stock option and underlying Common Stock.